Showing results (61-70 of 81) with videos related to
Sort By:
Pageof 9
Scientific Reports|September 24, 2021
Isolation and engineering of a Listeria grayi bacteriophageStephen Erickson, John Paulson, Matthew Brown, et al.Mayo Clinic Proceedings|September 10, 2015
Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the CommunityPrince Singh, Felicity T Enders, Lisa E Vaughan, et al.JAMA Pediatrics|February 12, 2014
Genetic epidemiology and nonsyndromic structural birth defects: from candidate genes to epigeneticsCharlotte A Hobbs, Shimul Chowdhury, Mario A Cleves, et al.Journal of the American Society of Nephrology : JASN|July 13, 2016
The Substantial Loss of Nephrons in Healthy Human Kidneys with AgingAleksandar Denic, John C Lieske, Harini A Chakkera, et al.Kidney360|February 18, 2025
Impact of an Interdisciplinary Chronic Kidney Disease Clinic on Disease Progression, Healthcare Use, and Social Determinants of HealthMaria B Mateo Chavez, Andrea Moran-Melendez, Lucy Salter, et al.Environmental Toxicology and Chemistry|March 9, 2022
The ECOTOXicology Knowledgebase: A Curated Database of Ecologically Relevant Toxicity Tests to Support Environmental Research and Risk AssessmentJennifer H Olker, Colleen M Elonen, Anne Pilli, et al.Pediatric Blood & Cancer|October 17, 2022
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcomaDouglas Harrison, Jonathan Gill, Michael Roth, et al.Molecular Cancer Therapeutics|December 10, 2020
ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing ConsortiumPooja Hingorani, Michael E Roth, Yifei Wang, et al.Pediatric Blood & Cancer|July 25, 2020
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortiumJonathan Gill, Wendong Zhang, Zhongting Zhang, et al.Pediatric Blood & Cancer|March 25, 2020
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing ConsortiumDouglas J Harrison, Jonathan D Gill, Michael E Roth, et al.Pageof 9